



Regeneron Ranked by Science Magazine as the #2 Employer in the Global Biopharmaceutical Industry

September 15, 2011

TARRYTOWN, N.Y., Sept. 15, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that *Science* magazine has ranked Regeneron as the #2 employer in the global biopharmaceutical industry in its annual survey of Top Employers.

"It is extremely satisfying for Regeneron to be recognized by *Science* as one of the best places to be a scientist," said Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of Regeneron. "It is a priority at Regeneron to create an environment where talented individuals can conduct groundbreaking science and where creativity and innovation are encouraged and recognized. We are grateful to *Science* for acknowledging our science-based culture and to our fantastic employees who give their best every day to the pursuit of important new medicines through scientific discoveries."

Details of the rankings and survey results will be published online on Sept. 16 at www.sciencereers.org/TopEmployers2011 and will be included in the Oct. 7 print issue of *Science*.

Regeneron, founded in 1988, currently has approximately 1,670 employees, of whom more than 300 hold Ph.D. or M.D. degrees. Regeneron has added about 1,000 employees since 2007, primarily to support its research and development programs. The Company's proprietary VelociGene® and VelocImmune® technologies were used to discover and develop eight fully-human monoclonal antibodies that are in clinical development. The Company's Trap fusion protein technology was applied to develop ARCALYST® (rilonacept) and two product candidates that have completed Phase 3 clinical studies.

About the Top Employers Survey

The *Science* and *Science Careers*' annual Top Employers Survey polls employees in the biotechnology, biopharmaceutical, pharmaceutical, and related industries to determine the driving characteristics of the best employers and to identify the 20 best employers from a universe of about 200 companies. Respondents to the web-based survey were asked to rate companies based on 23 characteristics, including financial strength, easy adaptation to change, and a research-driven environment.

According to *Science*, the 2011 global survey results were based on 3,784 responses from North America (80%), Europe (12%), and Asia/Pacific Rim (6%). A mathematical process was used to assign a unique score to rate each company's employer reputation.

About Regeneron Pharmaceuticals

Regeneron is a fully integrated biopharmaceutical company that discovers, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. In addition to ARCALYST® (rilonacept) Injection for Subcutaneous Use, which is approved for the treatment of a rare inflammatory condition, Regeneron has completed Phase 3 clinical trials of rilonacept for a new indication and of product candidates EYLEA™ (aflibercept injection; VEGF Trap Eye) in diseases of the eye and ZALTRAP® (aflibercept) (VEGF Trap) in colorectal cancer. EYLEA is currently under review with U.S. and European regulatory authorities. Additional therapeutic candidates developed from proprietary Regeneron technologies for creating fully human monoclonal antibodies are in earlier stage development programs in rheumatoid arthritis, pain, cholesterol reduction, allergic and immune conditions, and cancer. Additional information about Regeneron and recent news releases are available on www.regeneron.com.

Contact Information:

Michael Aberman, M.D.	Peter Dworkin
Investor Relations	Corporate Communications
914.345.7799	914.345.7640
michael.aberman@regeneron.com	peter.dworkin@regeneron.com

SOURCE Regeneron Pharmaceuticals, Inc.

News Provided by Acquire Media